Sitosterolemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for sitosterolemia. 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2033. Daily refresh.

1
Approved drugs
8
Active US patents
63/100
Avg vulnerability
—
Annual revenue covered

Originators in Sitosterolemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating sitosterolemia. Each bar = one year. Y-axis scaled to peak year (8 patents).

8
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zetia
EZETIMIBE
 Merck & Co. 8 63 — 2033-05-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10376470 Zetia method of use 62 2033-05-01
10376470 Zetia method of use 62 2033-05-01
9763885 Zetia method of use 62 2033-05-01
9763885 Zetia method of use 62 2033-05-01
9763885 Zetia method of use 62 2033-05-01
10376470 Zetia method of use 62 2033-05-01
9763885 Zetia method of use 62 2033-05-01
10376470 Zetia method of use 62 2033-05-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10376470 Zetia method of use 62 2033-05-01
10376470 Zetia method of use 62 2033-05-01
9763885 Zetia method of use 62 2033-05-01
9763885 Zetia method of use 62 2033-05-01
9763885 Zetia method of use 62 2033-05-01
10376470 Zetia method of use 62 2033-05-01
9763885 Zetia method of use 62 2033-05-01
10376470 Zetia method of use 62 2033-05-01

Related